Zomedica's TRUFORMA Demonstrates Superior Accuracy in Feline Hyperthyroidism Diagnosis Over CLIA Platforms

Zomedica Corp, a pioneer in veterinary health solutions, recently announced the publication of a research study showcasing the enhanced diagnostic accuracy of its TRUFORMA Bulk Acoustic Wave (BAW) platform for feline hyperthyroidism. This study, comparing TRUFORMA to widely used chemiluminescent immunoassay (CLIA) platforms, was published in the American Journal of Veterinary Research. Researchers found the TRUFORMA TSH-BAW assay to more effectively identify hyperthyroid cats, suggesting its potential as a primary screening tool alongside serum T4 tests for assessing thyroid function in cats.

Dr. Mark E. Peterson, the study's lead and a recognized figure in veterinary medicine, highlighted that conventional TSH-CLIA methods, primarily designed for canines, significantly lack sensitivity in diagnosing hyperthyroidism in cats. On the other hand, TRUFORMA's BAW technology offers precise, sensitive measurements unattainable by other diagnostics, making rapid, reliable in-clinic testing for thyroid and adrenal disorders possible. This not only brings reference lab quality into clinics but also delivers faster results, enhancing patient care.

Larry Heaton, Zomedica's CEO, voiced appreciation for the veterinary community's endorsement of TRUFORMA, underscoring the company's commitment to advancing animal healthcare through innovative diagnostics. Zomedica's ongoing clinical studies and recent developments are poised to further veterinary diagnostic capabilities, thereby improving care standards for companion animals.